Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More
Phase: II
STAR Ph2 enfortumab (ASG-22CE)Urothelial
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More
Phase: II
Biomarker Advcd Uro Cncer and FGFR Aber
Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002) Read More
Phase: IV
A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase: III
CONTESSA TRIO: Tes + PD-L1 HER2- LA/MBC
A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced orMetastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202) Read More
Phase: II
CONTESSA2: Ph2 HER2- HR+ BC
A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201) Read More
Phase: II
Ph1 SGN-LIV1A Metastatic BC
A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001) Read More
Phase: I
Ph1b Abemaciclib + SOC in mBC
A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH) Read More
Phase: I
Ph3 Pembro HR+/HER2- BC
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756) Read More
Phase: III
Ph2 alpelisib+fulves/letrozole HR+ HER2-
BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402) Read More
Phase: II
Ph 3 Ribo w/ endo ther HR+ HER2- BC
CLEE011O12301C (TRIO033): A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE). Read More
Phase: III
FLEX Registry: Evaluate New Gene Express
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read More
Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin plus Docetaxel in Triple Negative Breast Cancer (NeoPACT)
Phase 1/2, Multicenter, Non-randomized, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer
Phase: II
Ph3 IMMU-132 HR+, HER2- mBC
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician''s Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09) Read More
Phase: III
Ph 1b2 LIV1A+Pembro 1L mTNBC
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002) Read More
Phase: I/II
Ph 3 Tuca/Placbo + T-DM1 HER2+
STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016) Read More
Phase: III
Ph3 SYD985 HER2+ unresect adv/mBC
SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer Read More
Phase: III
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More
Phase: II
Ph3 TSR-042+car-pac vs plac+car-pac endo
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) (4010-03-001 / ENGOT EN-6 / GOG-3031) Read More
Phase: III
Ph 1/1b Immunotherapy Combo in NSCLC
(AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Read More
Phase: I
Ph 3 Sit+Nivo vs. Docetaxel NSCLC
516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy - SAPPHIRE Study Read More
Phase: III
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More
Phase: II
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789) Read More
Phase: III
Atezo Rollover for GNE & Roche
BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study Read More
Phase: II/III
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More
Phase: III
PhI/II PK Multi Tumor SubQ Nivo Mono
Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX) Read More
Phase: I/II
STAR PhIV Gazyva, Adv FL
(MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY) Read More
Phase: IV
STAR PhIV Gazyva, Adv FL
(MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY) Read More
Phase: IV
STAR BV in older pts w/1L cHL or PTCL
(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read More
Phase: II
Ph2 BGB-3111 Ibrut intolerant CLL/SLL
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib (BGB-3111-215) Read More
Phase: II
Ph1 INCB050465 B-Cell (CITADEL-112)
INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Read More
Phase: I
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More
Phase: II
PANOVA-3: 1L Gemcit + nab-pac pancreatic
PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27) Read More
Phase: III
STAR Ph2 Pemigatinib Solids FGFR
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More
Phase: II
STAR Ph2 Pemigatinib Solids FGFR
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More
Phase: II
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors Read More
Phase: I
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More
Phase: II
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Phase: I/II
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase: Ib
STAR Ph2 Erdafitinib FGFR Solid Tumors
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002) Read More
Phase: II
STAR Ph2 Erdafitinib FGFR Solid Tumors
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002) Read More
Phase: II
Phase 1b Multicohort Study of Anetumab Ravtansine for Mesothelin-Positive Advanced Solid Tumors (Study No 15834) in multiple indications (NSCLC, Thymic cancer, Triple negative breast cancer, gastric cancer, cholangiocarcinoma and pancreatic cancer)
Phase: Ib
STAR Ph3 FGFR erdafitinib urothelial
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More
Phase: III
STAR Ph3 FGFR erdafitinib urothelial
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More
Phase: III
STAR Ph2 enfortumab (ASG-22CE)Urothelial
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More
Phase: II
Biomarker Advcd Uro Cncer and FGFR Aber
Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002) Read More
Phase: IV
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt
QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302) Read More
Phase: III
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt
QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302) Read More
Phase: III